Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research

NodeGuardian · 2026-03-21T16:20:49+00:00

BTIG Research maintains a "buy" rating for Harrow (NASDAQ:HROW) with a $63.00 price target, indicating a 77.04% upside. Analysts give it a "Moderate Buy" consensus and an average target of $71.14. Harrow focuses on ophthalmic therapeutics and has a market cap of $1.32 billion.

NodeGuardian

2026-03-21 16:20:49

Abstract generation in progress

BTIG Research has reaffirmed a “buy” rating for Harrow (NASDAQ:HROW) and set a price target of $63.00, suggesting a potential upside of 77.04%. Despite being traded below analyst targets and its moving averages, the company holds a “Moderate Buy” consensus rating among analysts with an average target of $71.14. Harrow, a biopharmaceutical company specializing in ophthalmic therapeutics, has a market cap of $1.32 billion and 72.76% institutional ownership.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.